Societe Generale cut shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a buy rating to a hold rating in a research report sent to investors on Thursday, TheFlyOnTheWall.com reports.

Several other research firms have also recently issued reports on FMS. Commerzbank AG lowered shares of Fresenius Medical Care AG & Co. to a hold rating in a report on Friday, May 29th. RBC Capital boosted their price objective on shares of Fresenius Medical Care AG & Co. from $35.00 to $40.00 and gave the stock a sector perform rating in a research note on Friday, July 31st. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $41.10.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 0.91% during midday trading on Thursday, reaching $41.15. 78,366 shares of the company traded hands. The company has a 50 day moving average price of $42.26 and a 200 day moving average price of $41.45. The company has a market capitalization of $25.07 billion and a PE ratio of 23.66. Fresenius Medical Care AG & Co. has a 1-year low of $32.40 and a 1-year high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by $0.02. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.13 billion. Fresenius Medical Care AG & Co.’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period last year, the business posted $0.42 earnings per share. On average, analysts expect that Fresenius Medical Care AG & Co. will post $1.75 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...